Key result
Ischemic cardiomyopathy increased all-cause mortality compared to non-ischemic cardiomyopathy (HR 2.91) in Korean patients with severe heart failure, with similar sudden cardiac death risks.
Why the study?
Does the risk of all-cause mortality and sudden cardiac death in Korean patients with severe heart failure match the risks observed in the MADIT-II and DEFINITE standard therapy groups?
Cohort (n=275)
No
Does the risk of all-cause mortality and sudden cardiac death in Korean patients with severe heart failure match the risks observed in the MADIT-II and DEFINITE standard therapy groups?
Hazard Ratio: 2.91 (95% CI 1.52–5.59)
Absolute Event Rate: 40% vs 19%
p-value: p=0.001
Korean patients with severe heart failure have comparable mortality and sudden cardiac death risks to Western trial cohorts, supporting the use of established primary prevention ICD criteria in this population.
Ischemic cardiomyopathy was associated with higher mortality but similar SCD risk in Korean severe HF; leaves open direct applicability of Western primary-prevention ICD criteria.
BACKGROUND AND OBJECTIVES: Implantable cardioverter defibrillator (ICD) therapy is recommended as the primary tool for prevention of sudden cardiac death (SCD) in symptomatic patients with severe left ventricular dysfunction. There is a paucity of information on whether this recommendation is appropriate for the Korean population with severe heart failure. SUBJECTS AND METHODS: The study group consisted of 275 consecutive patients (mean age 65 years, 71% male) who met the ICD implantation criteria for primary prevention (left ventricular ejection fraction ≤30% and New York Heart Association functional class II or III). We analyzed the clinical characteristics and outcomes of an ischemic cardiomyopathy (ICMP) group (n=131) and a non-ischemic cardiomyopathy (NICMP) group (n=144). The outcomes of these 2 groups were compared with the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) conventional and Defibrillators in the Non-ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) standard therapy groups, respectively. RESULTS: Eighty patients (29%) died during a follow-up period of 40±17 months. The NICMP group had better all-cause mortality rates than the ICMP group (19% vs. 40%, p<0.001), however both groups had a similar incidence of SCD (7% vs. 10%, p=0.272). The 2-year all-cause mortality and SCD for the ICMP group were similar to those of the MADIT-II conventional therapy group (20% vs. 20%, 7% vs. 10%, respectively, all p>0.05). All-cause mortality and the incidence of SCD in the NICMP group were comparable to those of the DEFINITE standard therapy group (13% vs. 17%, 6% vs. 6%, respectively, all p>0.05). CONCLUSION: Korean patients with severe heart failure in both the ICMP and NICMP groups had all-caused mortality and risk of SCD comparable to patients in the MADIT-II and DEFINITE standard therapy groups. Therefore, the primary prevention criteria for ICD implantation would be appropriate in both Korean ICMP and NICMP patients.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2012) conducted a cohort in Severe heart failure (n=275). Ischemic cardiomyopathy vs. Non-ischemic cardiomyopathy was evaluated on All-cause mortality (HR 2.91, 95% CI 1.52-5.59, p=0.001). Ischemic cardiomyopathy increased all-cause mortality compared to non-ischemic cardiomyopathy (HR 2.91) in Korean patients with severe heart failure, with similar sudden cardiac death risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: